Provided by Tiger Trade Technology Pte. Ltd.

Editas Medicine

2.34
-0.0100-0.43%
Post-market: 2.340.0001+0.00%17:35 EST
Volume:2.48M
Turnover:5.87M
Market Cap:228.43M
PE:-1.00
High:2.46
Open:2.37
Low:2.34
Close:2.35
52wk High:4.54
52wk Low:0.9101
Shares:97.62M
Float Shares:89.58M
Volume Ratio:1.31
T/O Rate:2.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3493
EPS(LYR):-2.8795
ROE:-211.37%
ROA:-28.26%
PB:16.98
PE(LYR):-0.81

Loading ...

Editas Medicine reports in vivo preclinical PoC data for EDIT-401

TIPRANKS
·
Oct 09

Editas Medicine announces preclinical success for EDIT401 with over 90 percent LDL cholesterol reduction in animal models

Reuters
·
Oct 09

Editas Medicine Reports in Vivo Proof-of-Concept Data for Edit-401 at the European Society of Gene and Cell Therapy (Esgct) 32Nd Annual Congress

THOMSON REUTERS
·
Oct 09

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

GlobeNewswire
·
Oct 09

Editas Medicine to Present Oral CRISPR Gene Editing Data at European Society of Gene and Cell Therapy Congress

Reuters
·
Oct 06

Editas Medicine Announces Edit-401 Oral Presentation at the European Society of Gene and Cell Therapy (Esgct) 32Nd Annual Congress and Participation in Upcoming Investor Conferences

THOMSON REUTERS
·
Oct 06

While institutions invested in Editas Medicine, Inc. (NASDAQ:EDIT) benefited from last week's 11% gain, individual investors stood to gain the most

Simply Wall St.
·
Oct 06

Editas Medicine Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 05

Linda Burkly, EVP and Chief Scientific Officer, Reports Disposal of Common Shares in Editas Medicine Inc

Reuters
·
Sep 05

Editas Medicine Inc. CEO Neil O'Neill Reports Disposal of Common Shares

Reuters
·
Sep 05

Editas Medicine Inc. Unveils Presentation Highlighting Breakthrough Gene Editing Strategies and Pipeline

Reuters
·
Sep 03

BRIEF-Editas Medicine Inc - Nominates Edit-401 As Lead In Vivo Candidate

Reuters
·
Sep 02

Editas Medicine Inc - to Submit Ind or Cta for Edit-401 by Mid-2026

THOMSON REUTERS
·
Sep 02

Editas Medicine Inc - Edit-401 on Track for Human Proof-of-Concept Data by End of 2026

THOMSON REUTERS
·
Sep 02

Editas Medicine Inc - Nominates Edit-401 as Lead in Vivo Candidate

THOMSON REUTERS
·
Sep 02

Editas Medicine Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026

Reuters
·
Sep 02

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

GlobeNewswire
·
Aug 29

Editas Medicine Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 15

Editas Medicine Q2 EPS $(0.63) Misses $(0.38) Estimate, Sales $3.578M Beat $1.666M Estimate

Benzinga
·
Aug 13

Editas Medicine's CD19 HD Allo CAR T Program Receives IND/CTA Acceptance, Secures Milestone Payment Through Collaboration with Bristol Myers Squibb

Reuters
·
Aug 13